)
Visual21 Nov 2025
Data center suppliers
Terns Pharmaceuticals (TERN) investor relations material
Terns Pharmaceuticals Jefferies London Healthcare Conference 2025 summary
Complete event summary combining all related documents: earnings call transcript, report, and slide presentation.Jefferies London Healthcare Conference 2025 summary17 Nov, 2025
Key clinical data and efficacy
Phase I study in highly refractory CML patients showed unprecedented 64% major molecular response rate, double the previous best in similar studies.
Safety profile was favorable with only one discontinuation due to adverse events and no food effect observed, allowing flexible dosing.
TERN-701 demonstrated superior potency and target coverage compared to asciminib, including in preclinical models with BCR-ABL and Myristoyl Pocket mutations.
Data from partner Hansoh in China supported dose selection and safety insights, aiding rapid progression to pivotal trials.
Efficacy and safety data from both internal and Hansoh studies are congruent, with no contradictions observed.
Development strategy and regulatory plans
Plans to pursue both second-line plus and first-line pivotal trials, with the second-line plus study starting first and front-line study following within 6-12 months.
Dose selection for pivotal trials is ongoing, with decisions based on extended phase I data; no guidance on final dose expected before December.
Regulatory path is modeled after asciminib, targeting comparisons against second-generation TKIs and imatinib in the front line for fastest market entry.
Combination approaches are deprioritized in favor of monotherapy due to strong phase I results.
Ultimate goal includes enabling treatment-free remission (functional cure) in CML, pending long-term data.
Financial outlook and market positioning
Estimated direct costs for pivotal trials are under $100 million for second-line and under $150 million for front-line studies.
Company has cash runway into 2028 and aims to secure funding to complete pivotal trials before initiation.
Enrollment rates have increased due to compelling efficacy data, potentially accelerating timelines.
Management sees a de-risked path to market for a multi-billion dollar orphan drug, with phase I endpoints translating well to phase III.
No current plans to raise capital immediately; focus remains on trial execution and regulatory alignment.
How will pivotal trial strategy improve on asciminib?
What is the funding strategy for pivotal trials?
What key data details to expect at ASH update?
Partial view of Summaries dataset, powered by Quartr API
Research faster. Power your platform.
Next Terns Pharmaceuticals earnings date
Status Update8 Dec, 2025
Next Terns Pharmaceuticals earnings date
Status Update8 Dec, 2025
The essential earnings season companion
The #1 app for qualitative research. Live earnings calls, AI chat, transcripts, and more. All for free.
Live calls and transcripts
Listen to earnings calls, CMDs, investor conferences, and more – with a podcast-like experience.
Find what you need faster
Search for any keyword across all transcripts simultaneously.
Easily store key findings
Capturing important takeaways is as simple as it gets. Even during your lunch run or commute.
Your watchlist. Your dashboard.
Follow the companies that matter to you. Get a personalized feed with real-time updates.
Be the first to know
Set keyword alerts for any company, product, or competitor. Get notified the moment they're mentioned.
Consensus estimates
Access analyst consensus estimates, valuation multiples, and revenue segments splits.
All IR material in one place
The easiest way to stay updated during earnings season.
Global coverage
All events from public companies. Live and recorded.
Just click and listen
No webcast links. No manual registrations.
excellent app, it gives me free access to company earnings calls and annual reports. I also love the convenience of calls being available offline so I can listen in whilst doing other things and even when internet or WiFi isn't available.
)
Leroy DaleyApp Store
One of the very few apps you could call perfect. If something was to add to it, maybe the share price of the company when you search for it, but it's already excellent.
)
Eferix Drawings Google Play
This is genuinely one of the cleanest and fastest finance apps out there to track the market.
anuj283App Store
excellent app, it gives me free access to company earnings calls and annual reports. I also love the convenience of calls being available offline so I can listen in whilst doing other things and even when internet or WiFi isn't available.
Leroy DaleyApp Store
One of the very few apps you could call perfect. If something was to add to it, maybe the share price of the company when you search for it, but it's already excellent.
Eferix Drawings Google Play
This is genuinely one of the cleanest and fastest finance apps out there to track the market.
anuj283App Store
I can't remember the last time an app had such a positive impact on my investment process.
)
@ankurshah47_ x.com
Love the app! Quartr makes it really easy to keep track of earnings calls. It also includes the reports and slides to make it easier to follow along.
Amina0781App Store
Quartr is amazing, no way around it. It is the best right now for earnings calls, presentations, and the like.
@theshortbearx.com
I can't remember the last time an app had such a positive impact on my investment process.
@ankurshah47_ x.com
Love the app! Quartr makes it really easy to keep track of earnings calls. It also includes the reports and slides to make it easier to follow along.
Amina0781App Store
Quartr is amazing, no way around it. It is the best right now for earnings calls, presentations, and the like.
@theshortbearx.com
)
)
Frequently asked questions
Terns Pharmaceuticals Inc. is a clinical-stage biopharmaceutical company focusing on the development of a diverse portfolio of small-molecule therapeutic candidates. The company's research and development efforts are primarily focused on addressing serious diseases, including oncology, non-alcoholic steatohepatitis (NASH), and obesity.
Quartr provides global coverage of all investor relation material from public companies.
Mobile app: Research anytime, anywhere with the #1 app for live earnings calls, transcripts, analyst estimates, and more. All for free.
Desktop (Quartr Pro): The leading platform for qualitative research, used daily by top firms and financial institutions.
Quartr API: Build custom solutions powered by live earnings calls, live transcripts, filings and reports, slide presentations, and more.
Yes, the Quartr mobile app is free on both iOS and Android.
Yes. Quartr provides global, industry-leading live coverage of company events such as regular earnings calls, capital markets days, M&A announcements, and investor conferences. Live with zero delays. Just click and listen.
Yes, capturing important takeaways is as simple as it gets. Even during your lunch run or commute.
Yes. Follow the companies that matter to you. Get a personalized feed with real-time updates, a tailored earnings calendar, and instant alerts when earnings calls go live.
Yes. Set keyword alerts for any company, product, or competitor. Get notified the moment they're mentioned, regardless of who's talking.
Explore our global coverage